Safety, Efficacy and Pharmacokinetics of a New 10% Liquid Intravenous Immunoglobulin (IVIG) in Patients with Primary Immunodeficiency

INTRODUCTION: An investigational 10% liquid intravenous immunoglobulin (IVIG) was studied in 63 patients with primary immunodeficiency (PID) at 15 study sites. METHODS: Patients were treated every 3 or 4 weeks with 254–1029 mg/kg/infusion of IVIG. RESULTS: Overall, Biotest-IVIG infusions were well t...

Descripción completa

Detalles Bibliográficos
Autores principales: Wasserman, Richard L., Church, Joseph A., Stein, Mark, Moy, James, White, Martha, Strausbaugh, Steven, Schroeder, Harry, Ballow, Mark, Harris, James, Melamed, Isaac, Elkayam, David, Lumry, William, Suez, Daniel, Rehman, Syed M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2012
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3389237/
https://www.ncbi.nlm.nih.gov/pubmed/22392046
http://dx.doi.org/10.1007/s10875-012-9656-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3389237/
https://www.ncbi.nlm.nih.gov/pubmed/22392046
http://dx.doi.org/10.1007/s10875-012-9656-5

Ejemplares similares